News
Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.
Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...
Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...
Eli Lilly plans to acquire Verve for up to $1.3 billion. Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% ...
The Verve’s founder and lead singer, Richard Ashcroft, became a solo act in 2000. He recently released the single “Lover,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback